In an effort to introduce NISS to statisticians involved in the research and development of pharmaceutical products, NISS and Merck are jointly hosting a series of free virtual meetups, quarterly over the web, on emerging issues of interest to this community. The meeting will focus on the FDA draft guidance on "Multiple Endpoints in Clinical Trials" published in January this year.
HOW TO JOIN
Log into the WebEx on September 12, 2017 (meeting starts at 11:00 AM EDT but you can connect up to 15 minutes early). There is a limit of 500 lines.
- Meeting password: NISS17
You will receive audio via the "Audio Broadcast." This is a separate window that will automatically appear when you join the WebEx. Except for speakers/panelists, the audio line for all participants will be muted upon entry and will remain muted throughout the event.
If you can't access WebEx, you can connect by dialing
- Toll: +1 (443) 961-0100 (US)
- Global call-in numbers can be located at http://bit.ly/2gmHdRb
- Access code: 745 728 908
Note that though the lines are muted, you can ask questions to the panelists and chat with other attendees using the "Chat" panel. We ask you to please be respectful in preparing your comments.
For questions, contact officeadmin@NISS.org
Watch the recorded NISS-Merck Virtual Meet-up
11:00 – 11:05 NISS-Merck meetup with ground rules (Dan Holder, Merck)
11:05 – 11:10 What is NISS (Ray Bain, Merck)
11:10 – 11:25 Salient points in the FDA draft guidance (Alex Dmitrienko, Madiana Inc.)
11:25 – 11:35 Implementation of multiple comparison procedures (Frank Bretz, Novartis)
11:35 – 12:00 Panel discussions and Q&A
Moderator: Walt Offen (AbbVie)
Panelist: Lisa LaVange (FDA/CDER)
Alex Dmitrienko (Madiana Inc.)
Frank Bretz (Novartis)